Welcome to our dedicated page for ARS Pharms news (Ticker: SPRY), a resource for investors and traders seeking the latest updates and insights on ARS Pharms stock.
ARS Pharmaceuticals, Inc. develops and commercializes neffy, an epinephrine nasal spray for emergency treatment of Type I allergic reactions, including anaphylaxis. The company’s news commonly covers U.S. commercialization, product labeling, international approvals and licensing relationships for neffy, which is marketed as EURneffy in the European Union and the United Kingdom and under a separate trade name in China.
Recurring updates also include quarterly and annual financial results, clinical and scientific presentations on intranasal epinephrine, school-access programs, manufacturing and supply responsibilities for partners, and investor conference activity. The company’s allergy-treatment focus makes regulatory decisions, product access, clinical data and commercial launch progress central themes in its public announcements.
- 100% successful dosing rate in human factor studies - 24-month shelf life with temperature tolerance up to 122°F - Available at $199 for two doses (GoodRx price) - Eligible commercially insured patients pay as little as $25 - Partnership progress with major insurers including United Healthcare and Express Scripts
The company is implementing comprehensive support programs, including financial assistance and a Patient Assistance Program for eligible uninsured patients. The neffyinSchools program will provide the medication to participating eligible schools.
ARS Pharmaceuticals (NASDAQ: SPRY), a biopharmaceutical company focused on developing solutions for anaphylaxis protection, has scheduled a conference call and webcast for Wednesday, May 14, 2025, at 5:30 a.m. PT / 8:30 a.m. ET. The event will cover the company's first quarter 2025 financial results and business highlights.
Participants can obtain dial-in information by registering for the event. The webcast and presentation slides will be accessible through the Events & Presentations page in the Investors & Media section of the company's website. A replay will remain available for 30 days after the event.
ARS Pharmaceuticals (SPRY) reported strong financial results for Q4 and full year 2024, with total revenue of $89.1 million, including $7.3 million from neffy® sales since its September 2024 launch. The company achieved net income of $49.9 million in Q4 and $8.0 million for the full year.
Key highlights include FDA approval of neffy 1 mg for children aged four and older weighing 15-30 kg, expanding market reach to ~2 million younger children. The company secured favorable coverage decisions from major insurers and is on track for >60% commercial lives coverage by Q1 2025.
With $314.0 million in cash and investments as of December 31, 2024, ARS maintains a three-year operating runway. The company received a $145 million upfront payment from ALK-Abelló partnership, with $73.5 million recognized as Q4 revenue.
ARS Pharmaceuticals (NASDAQ: SPRY) has received FDA approval for neffy® 1 mg, the first needle-free epinephrine nasal spray for Type I Allergic Reactions, including anaphylaxis, in children aged 4+ years weighing 15-30 kg. The approval marks the first major innovation in epinephrine delivery for this patient population in over 35 years.
The approval is supported by extensive clinical trials showing pharmacokinetic and pharmacodynamic responses comparable to injectable epinephrine. Human factor studies demonstrated effective use by children as young as 10 and untrained caregivers. The device maintains stability at room temperature for 24 months.
neffy 1 mg will be available in the US by May 2025, with most commercially insured patients paying $25 or less for two devices. A cash price of $199 for two doses is available through BlinkRx, with additional support through the neffyConnect program and Patient Assistance Program for eligible individuals.
ARS Pharmaceuticals (SPRY), a biopharmaceutical company focused on anaphylaxis prevention, has scheduled its fourth quarter and full year 2024 financial results conference call for March 20, 2025, at 8:30 a.m. ET.
The company will also participate in upcoming investor events including:
- Leerink Partners Global Healthcare Conference with a fireside chat on March 10, 2025
- 37th Annual Roth Conference with investor meetings on March 16-18, 2025
A webcast replay will be available for 30 days following the earnings call on the company's website under the Events & Presentations page.
ARS Pharmaceuticals (NASDAQ: SPRY) announced that OptumRx, Cigna Healthcare, and Navitus Health Systems have added neffy® (epinephrine nasal spray) to their National Formularies. This expansion, occurring approximately five months after launch, provides access to half of all patients managing Type 1 allergic reactions, with coverage now available through 30 formulary platforms.
Patients insured by these providers will have access to neffy at the lowest branded copay without prior authorizations or step therapies. With ARS Pharma copay assistance, qualified patients can obtain neffy for $25. The company is currently working with UnitedHealthcare to add neffy to their formulary.
neffy 2 mg, the first FDA-approved epinephrine nasal spray, is designed for adults and children weighing ≥30 kg. A supplemental NDA for neffy 1 mg, intended for children over four years weighing 15-30 kg, has a PDUFA date of March 6, 2025, with expected availability by May 2025.
ARS Pharmaceuticals (NASDAQ: SPRY) announced nine presentations featuring data on neffy® (epinephrine nasal spray) at the 2025 AAAAI Annual Scientific Meeting. Key highlights include an oral presentation showing neffy's superior efficacy in Japanese patients during food challenges, with lower symptom scores within 10 minutes compared to traditional treatments.
The presentations will showcase comprehensive clinical research data, including pharmacokinetics and pharmacodynamics studies in Chinese subjects, demonstrating neffy's comparable efficacy and safety to intramuscular injection under various conditions. The studies confirm neffy's effectiveness in children four years or older weighing more than 15 kilograms.
neffy is the first and only FDA-approved needle-free treatment for Type I allergic reactions, including anaphylaxis, in adults and children weighing ≥30 kg (66 lbs). The event will be held from February 28 to March 3, 2025, in San Diego, California.
ARS Pharmaceuticals (SPRY), a biopharmaceutical company focused on protecting patients from severe allergic reactions and anaphylaxis, has announced its upcoming participation in the Oppenheimer 35th Annual Healthcare Conference.
The company's leadership, including Co-Founder, President and CEO Richard Lowenthal and Chief Commercial Officer Eric Karas, will engage in a fireside chat on February 12, 2025, at 2:40 p.m. ET. The conference will be held virtually, and management will also conduct one-on-one meetings with investors.
A live webcast of the fireside chat will be accessible online and through the company's website's Investors & Media section. The webcast recording will remain available for 90 days on the company's website.